{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:06:46Z","timestamp":1767848806958,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Sanofi Pasteur MSD"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3017-9","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T11:22:32Z","timestamp":1520248952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy"],"prefix":"10.1186","volume":"18","author":[{"given":"Carlo","family":"Giaquinto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Gabutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Tramontan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Raccanello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Poma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Scamarcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Cantarutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Perinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Cornen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Ballandras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Souverain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Hartwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"key":"3017_CR1","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","volume":"368","author":"U Heininger","year":"2006","unstructured":"Heininger U, Seward JF. Varicella. Lancet. 2006;368:1365\u201376.","journal-title":"Lancet"},{"key":"3017_CR2","first-page":"204","volume-title":"Control of communicable diseases manual","author":"DL Heymann","year":"2003","unstructured":"Heymann DL. Control of communicable diseases manual. 18th ed. Washington DC: American Public Health Association; 2003. p. 204.","edition":"18"},{"key":"3017_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0264-410X(98)00161-3","volume":"17","author":"L Coudeville","year":"1999","unstructured":"Coudeville L, Paree F, Lebrun T, Sailly J. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine. 1999;17:142\u201351.","journal-title":"Vaccine"},{"key":"3017_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2165\/00019053-200422130-00003","volume":"22","author":"L Coudeville","year":"2004","unstructured":"Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux B. Varicella vaccination in Italy: an economic evaluation of different scenarios. PharmacoEconomics. 2004;22:839\u201355.","journal-title":"PharmacoEconomics"},{"key":"3017_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1524-4733.2005.04005.x","volume":"8","author":"L Coudeville","year":"2005","unstructured":"Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health. 2005;8:209\u201322.","journal-title":"Value Health"},{"key":"3017_CR6","first-page":"265","volume":"89","author":"Varicella and herpes zoster vaccines","year":"2014","unstructured":"Varicella and herpes zoster vaccines. WHO position paper, June 2014. Wkly Epidemiol Rec. 2014;89:265\u201387.","journal-title":"Wkly Epidemiol Rec"},{"key":"3017_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1097\/01.inf.0000172901.29621.e9","volume":"24","author":"H Shinefield","year":"2005","unstructured":"Shinefield H, Black S, Williams WR, Marchant C, Reisinger K, Stewart T, et al. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24:670\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"3017_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/01.inf.0000172902.25009.a1","volume":"24","author":"H Shinefield","year":"2005","unstructured":"Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24:665\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"3017_CR9","first-page":"E071101","volume":"12","author":"V Baldo","year":"2007","unstructured":"Baldo V, Ferro A, Napoletano G, Milani S, Bertoncello L, Baldovin T, et al. Universal varicella vaccination in the Veneto region, Italy: launch of a programme targeting all children aged 14 months and susceptible adolescents. Euro Surveill. 2007;12:E071101.","journal-title":"Euro Surveill"},{"key":"3017_CR10","unstructured":"Ministero della Salute. Indicazioni in merito alla somministrazione della vaccinazione contro la varicella in et\u00e0 pediatrica. Circolare 10\/10\/2012, n. 21509. 2012. \n                    http:\/\/www.trovanorme.salute.gov.it\/norme\/renderNormsanPdf?anno=0&codLeg=44156&parte=1%20&serie=\n                    \n                  . Accessed 26 Dec 2016. Italian."},{"key":"3017_CR11","unstructured":"Italian National Institute of Statistics. I.stat website. Popolazione e famiglie: Indicatori demografici. \n                    http:\/\/dati.istat.it\/Index.aspx?DataSetCode=DCIS_INDDEMOG1\n                    \n                  . Accessed 26 Dec 2016."},{"key":"3017_CR12","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.1016\/j.vaccine.2013.07.006","volume":"31","author":"G Hanquet","year":"2013","unstructured":"Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013;31:5634\u201342.","journal-title":"Vaccine"},{"key":"3017_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00001648-200301000-00024","volume":"14","author":"A Nicolosi","year":"2003","unstructured":"Nicolosi A, Sturkenboom M, Mannino S, Arpinelli F, Cantarutti L, Giaquinto C. The incidence of varicella: correction of a common error. Epidemiology. 2003;14:99\u2013102.","journal-title":"Epidemiology"},{"key":"3017_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4161\/hv.2.5.3246","volume":"2","author":"BJ Kuter","year":"2006","unstructured":"Kuter BJ, Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S, et al. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccin. 2006;2:205\u201314.","journal-title":"Hum Vaccin"},{"key":"3017_CR15","doi-asserted-by":"publisher","first-page":"e1389","DOI":"10.1542\/peds.2012-3303","volume":"131","author":"R Baxter","year":"2013","unstructured":"Baxter R, Ray P, Tran TN, Black S, Shinefield HR, Coplan PM, et al. Long-term effectiveness of varicella vaccine: a 14-year, prospective cohort study. Pediatrics. 2013;131:e1389\u201396.","journal-title":"Pediatrics"},{"key":"3017_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","volume":"23","author":"B Kuter","year":"2004","unstructured":"Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132\u20137.","journal-title":"Pediatr Infect Dis J"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3017-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:12:31Z","timestamp":1551744751000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3017-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3017"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3017-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,5]]},"assertion":[{"value":"17 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics committee of the Azienda Ospedaliera of Padova reviewed the study related documents and approved the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Data from children whose parents have signed an informed consent are collected and transmitted to a central Pedianet database in Padova after anonymisation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"CG received consultancy and research grants to his referral Institutions from SPMSD, Merck, GSK-Bio, Gilead, ViiV-Healthcare; GG received grants from Sanofi Pasteur MSD, GSK Biologicals SA, Novartis, Pfizer, and Sequirus for taking part to advisory boards, expert meetings, for acting as speaker and\/or organizer of meetings\/congresses and as principal investigator and chief of O.U. in randomized controlled trials, and he recently became a member of the Regional Commission on Vaccines (Emilia Romagna Region, Italy) without any decision making role; the Commission has only a technical and scientific role; VB received grants from GSK, SPMSD, Novartis, and Pfizer for taking part in advisory boards, expert meetings, being a speaker or an organizer of congresses\/conferences, and acting as promoter of epidemiological studies partially supported by vaccine producers; LC received research grants from SPMSD, and GSK-Bio; EP, XC, ST, CB, and SH were employees of Sanofi Pasteur MSD during the study period; AS was working as a consultant for Sanofi Pasteur MSD, mandated by AIXIAL; MV, LT, NR, FR, ChP, ASc, and RL don\u2019t have any competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"103"}}